Oruka Therapeutics, Inc. (ORKA) - Total Assets
Based on the latest financial reports, Oruka Therapeutics, Inc. (ORKA) holds total assets worth $509.25 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Oruka Therapeutics, Inc. (ORKA) net assets for net asset value and shareholders' equity analysis.
Oruka Therapeutics, Inc. - Total Assets Trend (2005–2024)
This chart illustrates how Oruka Therapeutics, Inc.'s total assets have evolved over time, based on quarterly financial data.
Oruka Therapeutics, Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Oruka Therapeutics, Inc.'s total assets of $509.25 Million consist of 95.2% current assets and 4.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 15.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2005–2024)
This chart illustrates how Oruka Therapeutics, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ORKA stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Oruka Therapeutics, Inc.'s current assets represent 95.2% of total assets in 2024, an increase from 79.4% in 2005.
- Cash Position: Cash and equivalents constituted 15.6% of total assets in 2024, down from 35.0% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 4.0% in 2005.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Oruka Therapeutics, Inc. Competitors by Total Assets
Key competitors of Oruka Therapeutics, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Oruka Therapeutics, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 16.94 | 22.89 | 14.28 |
| Quick Ratio | 16.94 | 22.89 | 14.28 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $334.20 Million | $394.91 Million | $46.47 Million |
Oruka Therapeutics, Inc. - Advanced Valuation Insights
This section examines the relationship between Oruka Therapeutics, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 3.94 |
| Asset Growth Rate (YoY) | 946.0% |
| Total Assets | $396.02 Million |
| Market Capitalization | $1.56 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Oruka Therapeutics, Inc.'s assets at a significant premium (3.94x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Oruka Therapeutics, Inc.'s assets grew by 946.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Oruka Therapeutics, Inc. (2005–2024)
The table below shows the annual total assets of Oruka Therapeutics, Inc. from 2005 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $396.02 Million | +945.98% |
| 2023-12-31 | $37.86 Million | -12.12% |
| 2022-12-31 | $43.09 Million | -21.56% |
| 2021-12-31 | $54.92 Million | +8.91% |
| 2020-12-31 | $50.43 Million | +490.78% |
| 2019-12-31 | $8.54 Million | +25.07% |
| 2018-12-31 | $6.83 Million | -44.80% |
| 2017-12-31 | $12.37 Million | -49.79% |
| 2016-12-31 | $24.63 Million | -37.76% |
| 2015-12-31 | $39.57 Million | +145.31% |
| 2014-12-31 | $16.13 Million | -5.57% |
| 2013-12-31 | $17.08 Million | +431.88% |
| 2012-12-31 | $3.21 Million | -50.60% |
| 2011-12-31 | $6.50 Million | -20.28% |
| 2010-12-31 | $8.16 Million | -12.97% |
| 2009-12-31 | $9.37 Million | -15.41% |
| 2008-12-31 | $11.08 Million | -90.82% |
| 2007-12-31 | $120.68 Million | -34.56% |
| 2006-12-31 | $184.41 Million | +70.67% |
| 2005-12-31 | $108.05 Million | -- |
About Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-1… Read more